[1]
|
Jackman, D., Pao, W., Riely, G.J., et al. (2010) Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 28, 357-360.
https://doi.org/10.1200/JCO.2009.24.7049
|
[2]
|
Gandara, D.R., Li, T., Lara, P.N., et al. (2014) Acquired Resistance to Targeted Therapies against Oncogene-Driven Non-Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications. Clinical Lung Cancer, 15, 1-6. https://doi.org/10.1016/j.cllc.2013.10.001
|
[3]
|
Yang, J.J., Chen, H.J., Yan, H.H., et al. (2013) Clinical Modes of EGFR Tyrosine Kinase Inhibitor Failure and Subsequent Management in Advanced Non-Small Cell Lung Cancer. Lung Cancer, 79, 33-39.
https://doi.org/10.1016/j.lungcan.2012.09.016
|
[4]
|
Weickhardt, A.J., Scheier, B., Burke, J.M., et al. (2012) Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 7, 1807-1814. https://doi.org/10.1097/JTO.0b013e3182745948
|
[5]
|
Gomez, D.R., Niibe, Y. and Chang, J.Y. (2012) Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer. Pulmonary Medicine, 396, 592. https://doi.org/10.1155/2012/396592
|
[6]
|
Lee, K., Kim, Y., Jung, H.A., et al. (2019) Repeat Biopsy Procedures and T790M Rates after Afatinib, Gefitinib, or Erlotinib Therapy in Patients with Lung Cancer. Lung Cancer, 130, 87-92.
https://doi.org/10.1016/j.lungcan.2019.01.012
|
[7]
|
Yu, H.A., Tian, S.K., Drilon, A.E., et al. (2015) Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Spe- cific EGFR Inhibitor. JAMA Oncology, 1, 982-984. https://doi.org/10.1001/jamaoncol.2015.1066
|
[8]
|
Zhu, S.J., Zhao, P., Yang, J., et al. (2018) Structural Insights into Drug Development Strategy Targeting EGFR T790M/ C797S. Oncotarget, 9, 13652-13665. https://doi.org/10.18632/oncotarget.24113
|
[9]
|
Menon, R., Müller, J., Schneider, P., et al. (2016) A Novel EGFR C797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay. Journal of Thoracic Oncology, 11, e105-e107. https://doi.org/10.1016/j.jtho.2016.04.005
|
[10]
|
Chen, K., Zhou, F., Shen, W., et al. (2017) Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. Journal of Thoracic Oncology, 12, e65-e68.
https://doi.org/10.1016/j.jtho.2016.12.024
|
[11]
|
Ou, S.I., Cui, J., Schrock, A.B., et al. (2019) Erratum to “Emergence of Novel and Dominant Acquired EGFR Solvent-Front Mutations at Gly796 (G796S/R) Together with C797S/G and L792F/H Mutations in One EGFR (L858R/ T790M) NSCLC Patient Who Progressed on Osimertinib” [Lung Cancer, 108 (June 2017) 228-231]. Lung Cancer, 138, 141. https://doi.org/10.1016/j.lungcan.2019.08.013
|
[12]
|
Bersanelli, M., Minari, R., Bordi, P., et al. (2016) L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC. Journal of Thoracic Oncology, 11, e121-e123.
https://doi.org/10.1016/j.jtho.2016.05.019
|
[13]
|
Balak, M.N., Gong, Y., Riely, G.J., et al. (2006) Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clinical Cancer Research, 12, 6494-6501. https://doi.org/10.1158/1078-0432.CCR-06-1570
|
[14]
|
Yamaguchi, F., Fukuchi, K., Yamazaki, Y., et al. (2014) Acquired Resistance L747S Mutation in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Naïve Patient: A Report of Three Cases. Oncology Letters, 7, 357-360.
https://doi.org/10.3892/ol.2013.1705
|
[15]
|
Ho, C.C., Liao, W.Y., Lin, C.A., et al. (2017) Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. Journal of Thoracic Oncology, 12, 567-572. https://doi.org/10.1016/j.jtho.2016.11.2231
|
[16]
|
Chabon, J.J., Simmons, A.D., Lovejoy, A.F., et al. (2016) Circulating Tumour DNA Profiling Reveals Heterogeneity of EGFR Inhibitor Resistance Mechanisms in Lung Cancer Patients. Nature Communications, 7, Article No. 11815.
https://doi.org/10.1038/ncomms11815
|
[17]
|
Cortot, A.B., Repellin, C.E., Shimamura, T., et al. (2013) Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. Cancer Research, 73, 834-843.
https://doi.org/10.1158/0008-5472.CAN-12-2066
|
[18]
|
Zhang, Z., Lee, J.C., Lin, L., et al. (2012) Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer. Nature Genetics, 44, 852-860. https://doi.org/10.1038/ng.2330
|
[19]
|
Takezawa, K., Pirazzoli, V., Arcila, M.E., et al. (2012) HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation. Cancer Discovery, 2, 922-933. https://doi.org/10.1158/2159-8290.CD-12-0108
|
[20]
|
Sos, M.L., Koker, M., Weir, B.A., et al. (2009) PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. Cancer Research, 69, 3256-3261.
https://doi.org/10.1158/0008-5472.CAN-08-4055
|
[21]
|
Bean, J., Brennan, C., Shih, J.Y., et al. (2007) MET Amplification Occurs with or without T790M Mutations in EGFR Mutant Lung Tumors with Acquired Resistance to Gefitinib or Erlotinib. Proceedings of the National Academy of Sci- ences of the United States of America, 104, 20932-20937. https://doi.org/10.1073/pnas.0710370104
|
[22]
|
Kim, T.M., Song, A., Kim, D.W., et al. (2015) Mechanisms of Acquired Resistance to AZD9291. Journal of Thoracic Oncology, 10, 1736-1744. https://doi.org/10.1097/JTO.0000000000000688
|
[23]
|
Engelman, J.A., Zejnullahu, K., Mitsudomi, T., et al. (2007) MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 316, 1039-1043. https://doi.org/10.1126/science.1141478
|
[24]
|
Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. (2011) Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Science Translational Medicine, 3, 75ra26.
https://doi.org/10.1126/scitranslmed.3002003
|
[25]
|
Niederst, M.J., Sequist, L.V., Poirier, J.T., et al. (2015) RB Loss in Resistant EGFR Mutant Lung Adenocarcinomas That Transform to Small-Cell Lung Cancer. Nature Communications, 6, 6377.
|
[26]
|
Yao, Z., Fenoglio, S., Gao, D.C., et al. (2010) TGF-IL-6 Axis Mediates Selective and Adaptive Mechanisms of Resistance to Molecular Targeted Therapy in Lung Cancer. Proceedings of the National Academy of Sciences of the United States of America, 107, 15535-15540. https://doi.org/10.1073/pnas.1009472107
|
[27]
|
Yamamoto, M., Serizawa, T., Shuto, T., et al. (2014) Stereotactic Radiosurgery for Patients with Multiple Brain Metastases (JLGK0901): A Multi-Institutional Prospective Observational Study. The Lancet Oncology, 15, 387-395.
https://doi.org/10.1016/S1470-2045(14)70061-0
|
[28]
|
Welsh, J.W., Komaki, R., Amini, A., et al. (2013) Phase II Trial of Erlotinib plus Concurrent Whole-Brain Radiation Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 31, 895-902. https://doi.org/10.1200/JCO.2011.40.1174
|
[29]
|
Kocher, M., Soffietti, R., Abacioglu, U., et al. (2011) Adjuvant Whole-Brain Radiotherapy versus Observation after Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study. Journal of Clinical Oncology, 29, 134-141. https://doi.org/10.1200/JCO.2010.30.1655
|
[30]
|
Grommes, C., Oxnard, G., Kris, M.G., et al. (2011) “Pulsatile” High-Dose Weekly Erlotinib for CNS Metastases from EGFR Mutant Non-Small Cell Lung Cancer. Neuro-Oncology, 13, 1364-1369. https://doi.org/10.1093/neuonc/nor121
|
[31]
|
Patchell, R.A., Tibbs, P.A., Walsh, J.W., et al. (1990) A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain. The New England Journal of Medicine, 322, 494-500.
https://doi.org/10.1056/NEJM199002223220802
|
[32]
|
Ni, Y., Bi, J., Ye, X., et al. (2016) Local Microwave Ablation with Continued EGFR Tyrosine Kinase Inhibitor as a Treatment Strategy in Advanced Non-Small Cell Lung Cancers That Developed Extra-Central Nervous System Oligoprogressive Disease during EGFR Tyrosine Kinase Inhibitor Treatment. Medicine (Baltimore), 95, e3998.
https://doi.org/10.1097/MD.0000000000003998
|
[33]
|
Yu, H.A., Sima, C.S., Huang, J., et al. (2013) Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 8, 346-351.
https://doi.org/10.1097/JTO.0b013e31827e1f83
|
[34]
|
Park, K., Yu, C.J., Kim, S.W., et al. (2016) First-Line Erlotinib Therapy until and beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients with Epidermal Growth Factor Receptor Mutation-Positive Non- Small-Cell Lung Cancer: The ASPIRATION Study. JAMA Oncology, 2, 305-312.
https://doi.org/10.1001/jamaoncol.2015.4921
|
[35]
|
Kobayashi, S., Boggon, T.J., Dayaram, T., et al. (2005) EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib. The New England Journal of Medicine, 352, 786-792. https://doi.org/10.1056/NEJMoa044238
|
[36]
|
Wu, S.G., Liu, Y.N., Tsai, M.F., et al. (2016) The Mechanism of Acquired Resistance to Irreversible EGFR Tyrosine Kinase Inhibitor-Afatinib in Lung Adenocarcinoma Patients. Oncotarget, 7, 12404-12413.
https://doi.org/10.18632/oncotarget.7189
|
[37]
|
Yang, J.C., Ahn, M.J., Kim, D.W., et al. (2017) Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. Journal of Clinical Oncology, 35, 1288-1296.
https://doi.org/10.1200/JCO.2016.70.3223
|
[38]
|
Wu, Y.L., Zhang, L., Kim, D.W., et al. (2018) Phase Ib/II Study of Capmatinib (INC280) plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dys- regulated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 36, 3101-3109.
https://doi.org/10.1200/JCO.2018.77.7326
|
[39]
|
Neal, J.W., Dahlberg, S.E., Wakelee, H.A., et al. (2016) Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as Second-Line or Third-Line Treatment of Patients with EGFR Wild-Type Advanced Non-Small-Cell Lung Cancer (ECOG-ACRIN 1512): A Randomised, Controlled, Open-Label, Multicentre, Phase 2 Trial. The Lancet Oncology, 17, 1661-1671. https://doi.org/10.1016/S1470-2045(16)30561-7
|
[40]
|
Bowles, D.W., Weickhardt, A. and Jimeno, A. (2013) Afatinib for the Treatment of Patients with EGFR-Positive Non- Small Cell Lung Cancer. Drugs Today, 49, 523-535. https://doi.org/10.1358/dot.2013.49.09.2016610
|
[41]
|
Landi, L., Tiseo, M., Chiari, R., et al. (2014) Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients with Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 15, 411-417.e4. https://doi.org/10.1016/j.cllc.2014.07.002
|
[42]
|
Ludovini, V., Bianconi, F., Pistola, L., et al. (2011) Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations Are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 6, 707-715.
https://doi.org/10.1097/JTO.0b013e31820a3a6b
|
[43]
|
Tan, S.W., Lim, K.H., Tai, W.M., et al. (2013) A Phase Ib Safety and Tolerability Study of a Pan Class I PI3K Inhibitor Buparlisib (BKM120) and Gefitinib (gef) in EGFR TKI-Resistant NSCLC. Journal of Thoracic Oncology, 31, 8107-8107. https://doi.org/10.1200/jco.2013.31.15_suppl.8107
|
[44]
|
Gay, C.M., Balaji, K., Byers, L.A. (2017) Giving AXL the Axe: Targeting AXL in Human Malignancy. British Journal of Cancer, 116, 415-423. https://doi.org/10.1038/bjc.2016.428
|
[45]
|
Mok, T.S.K., Kim, S.W., Wu, Y.L., et al. (2017) Gefitinib plus Chemotherapy versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. Journal of Clinical Oncology, 35, 4027-4034.
https://doi.org/10.1200/JCO.2017.73.9250
|
[46]
|
Johnson, M.L., Yu, H.A., Hart, E.M., et al. (2015) Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 33, 1666-1673. https://doi.org/10.1200/JCO.2014.59.7328
|
[47]
|
Soria, J.C., Ohe, Y., Vansteenkiste, J., et al. (2018) Osimertinib in Untreated EGFR-Mutated Advanced Non-Small- Cell Lung Cancer. The New England Journal of Medicine, 378, 113-125. https://doi.org/10.1056/NEJMoa1713137
|
[48]
|
Wang, Y., Yang, N., Zhang, Y., et al. (2020) Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Acti- vating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy. Journal of Thoracic Oncology, 15, 1369-1375. https://doi.org/10.1016/j.jtho.2020.04.014
|
[49]
|
Zhou, Z., Zhao, Y., Shen, S., et al. (2019) Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 14, e157-e159. https://doi.org/10.1016/j.jtho.2019.04.020
|
[50]
|
Arulananda, S., Do, H., Musafer, A., et al. (2017) Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 12, 1728-1732.
https://doi.org/10.1016/j.jtho.2017.08.006
|
[51]
|
Sequist, L.V., Han, J.Y., Ahn, M.J., et al. (2020) Osimertinib plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small-Cell Lung Cancer after Progression on EGFR Tyrosine Kinase Inhibitors: Interim Results from a Multicentre, Open-Label, Phase 1b Study. The Lancet Oncology, 21, 373-386.
https://doi.org/10.1016/S1470-2045(19)30785-5
|
[52]
|
Vijayaraghavan, S., Lipfert, L., Chevalier, K., et al. (2020) Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/ cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Molecular Cancer Therapeutics, 19, 2044-2056. https://doi.org/10.1158/1535-7163.MCT-20-0071
|
[53]
|
Peters, S., Stahel, R., Bubendorf, L., et al. (2019) Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clinical Cancer Research, 25, 64-72. https://doi.org/10.1158/1078-0432.CCR-18-1590
|
[54]
|
Hsu, C.C., Liao, B.C., Liao, W.Y., et al. (2020) Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 15, 50-61.
https://doi.org/10.1016/j.jtho.2019.09.006
|
[55]
|
Eberlein, C.A., Stetson, D., Markovets, A.A., et al. (2015) Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Research, 75, 2489-2500. https://doi.org/10.1158/0008-5472.CAN-14-3167
|
[56]
|
Oxnard, G.R., Yang, J.C., Yu, H., et al. (2020) TATTON: A Multi-Arm, Phase Ib Trial of Osimertinib Combined with Selumetinib, Savolitinib, or Durvalumab in EGFR-Mutant Lung Cancer. Annals of Oncology, 31, 507-516.
https://doi.org/10.1016/j.annonc.2020.01.013
|
[57]
|
Xu, H., Shen, J., Xiang, J., et al. (2019) Characterization of Acquired Receptor Tyrosine-Kinase Fusions as Mechanisms of Resistance to EGFR Tyrosine-Kinase Inhibitors. Cancer Management and Research, 11, 6343-6351.
https://doi.org/10.2147/CMAR.S197337
|
[58]
|
Drilon, A., Rekhtman, N., Arcila, M., et al. (2016) Cabozantinib in Patients with Advanced RET-Rearranged Non- Small-Cell Lung Cancer: An Open-Label, Single-Centre, Phase 2, Single-Arm Trial. The Lancet Oncology, 17, 1653-1660.
https://doi.org/10.1016/S1470-2045(16)30562-9
|
[59]
|
Piotrowska, Z., Isozaki, H., Lennerz, J.K., et al. (2018) Landscape of Acquired Resistance to Osimertinib in EGFR- Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discovery, 8, 1529-1539. https://doi.org/10.1158/2159-8290.CD-18-1022
|
[60]
|
Yu, H.A., Paz-Ares, L.G., Yang, J.C., et al. (2021) Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer. Clinical Cancer Research, 27, 992-1002. https://doi.org/10.1158/1078-0432.CCR-20-1690
|
[61]
|
Yonesaka, K., Takegawa, N., Watanabe, S., et al. (2019) An HER3-Targeting Antibody-Drug Conjugate Incorporating a DNA Topoisomerase I Inhibitor U3-1402 Conquers EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC. Oncogene, 38, 1398-1409. https://doi.org/10.1038/s41388-018-0517-4
|
[62]
|
Schoenfeld, A.J., Chan, J.M., Kubota, D., et al. (2020) Tumor Analyses Reveal Squamous Transformation and Off- Target Alterations as Early Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutant Lung Cancer. Clinical Cancer Research, 26, 2654-2663. https://doi.org/10.1158/1078-0432.CCR-19-3563
|
[63]
|
Oxnard, G.R., Hu, Y., Mileham, K.F., et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients with EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncology, 4, 1527- 1534. https://doi.org/10.1001/jamaoncol.2018.2969
|